US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Arctic Bioscience – Q3 2024 Operational update

Highlights Q3 2024: · The HeROPA 6-month read-out showed an effect close to the assumed effect level in the high dose active treatment arm, while the placebo rate was unexpectedly high, preventing the achievement of the primary end-point. The HeROPA study is still ongoing and placebo controlled for 52 weeks ending Q1 2025 · Nutra revenues YTD Q3 are NOK 27,8 million (NOK 23,9 million), expecting a growth of 25-30 % end of 2024 compared to 2023 · Asian markets with strong development; expecting 65-70 % growth compared to 2023 · European market also developing well; expecting 45 %

Arctic Bioscience – Mandatory notification of trade

Christer Valderhaug, CEO at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 1,72 per share. Following the transaction, Christer Valderhaug holds 57,630 shares in Arctic Bioscience.Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Arctic Bioscience – Mandatory notification of trade

Eggesbø Eiendom AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today sold 520,240 shares in Arctic Bioscience at an average price of NOK 2,23 per share. Following the transaction, Eggesbø Eiendom AS holds 0 shares in Arctic Bioscience.Member of the Board at Arctic Bioscience, Per Magne Eggesbø, is the chairman of the board and CEO of Eggesbø Eiendom AS, and owns 21% of the company. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements

Arctic Bioscience – Mandatory notification of trade

Daniele Mancinelli, CTO at Arctic Bioscience, has today bought 2,000 shares in Arctic Bioscience at an average price of NOK 2,40 per share. Following the transaction, Daniele Mancinelli holds 58,840 shares in Arctic Bioscience. In addition, Daniele Mancinelli indirectly holds 76,180 shares in Arctic Bioscience through 60% ownership in Futuron AS.Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Arctic Bioscience – Mandatory notification of trade

Siglar AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 20,000 shares in Arctic Bioscience at an average price of NOK 2,32 per share. Following the transaction, Siglar AS holds 20,000 shares in Arctic Bioscience. In addition, Siglar AS holds 50% ownership of Capra Invest AS, which holds 1,544,450 in Arctic Bioscience.Chairman of the Board at Arctic Bioscience, Harald Nordal, is the owner of Siglar AS. Please refer to the attached notification of trading for further details.  This information is subject to

Arctic Bioscience – Mandatory notification of trade

Hogne Hallaråker, CSO at Arctic Bioscience, has today bought 5,000 shares in Arctic Bioscience at an average price of NOK 2,50 per share. Following the transaction, Hogne Hallaråker holds 5,000 shares in Arctic Bioscience. In addition, Gold Coast Nutrition, a company controlled by Hogne Hallaråker, holds 460,000 shares in Arctic Bioscience.Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Arctic Bioscience – Mandatory notification of trade

Runhild Gammelsæter, Medical Director at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 2,86 per share. Following the transaction, Runhild Gammelsæter holds 34,774 shares in Arctic Bioscience.Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Arctic Bioscience – Mandatory notification of trade

Gold Coast Nutrition, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 5,000 shares in Arctic Bioscience at an average price of NOK 3,00 per share. Following the transaction, Gold Coast Nutrition holds 460,000 shares in Arctic Bioscience.CSO at Arctic Bioscience, Hogne Hallaråker, is the owner of Gold Coast Nutrition. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the

Arctic Bioscience – Presentation for today’s webcast

With reference to yesterday’s stock exchange release regarding webcast to be hosted today at 12:00 CET to present the results from the HeROPA read-out.Attached is the presentation material which will be presented at this webcast. The webcast will be hosted by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. Webcast details: Date: Wednesday 16[th] of October 2024 Time: 12:00 CET Format: Webcast Language: English The presentation can be accessed through the link below: Link: https://channel.royalcast.com/landingpage/hegnarmedia/20241016_1/ This

Arctic Bioscience – Mandatory notification of trade

Gold Coast Nutrition, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 5,000 shares in Arctic Bioscience at an average price of NOK 3,08 per share. Following the transaction, Gold Coast Nutrition holds 455,000 shares in Arctic Bioscience.CSO at Arctic Bioscience, Hogne Hallaråker, is the owner of Gold Coast Nutrition. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the

Arctic Bioscience – Invitation to webcast – HeROPA read-out

With reference to stock exchange release regarding the results from the HeROPA clinical trial read-out.Arctic Bioscience will host a webcast tomorrow Wednesday 16[th] of October 2024 at 12:00 CET, to present the results from the HeROPA read-out. The webcast will be hosted by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. Webcast details: Date: Wednesday 16[th] of October 2024 Time: 12:00 CET Format: Webcast Language: English The presentation can be accessed through the link below: Link: https://channel.royalcast.com/landingpage/hegnarmedia/

Arctic Bioscience - Announces top-line results from the phase 2b HeROPA study

All patients have passed 6 months of treatment in the HeROPA phase 2b clinical study, which compared HRO350 to placebo. While the high dose active treatment arm showed an effect close to the assumed effect level, the placebo rate was unexpectedly high, preventing the achievement of the primary end-point. The HeROPA study is still ongoing and placebo controlled for 52 weeks."We have strong confidence in our phospholipid-based technology platform for resolving inflammation. The study is still ongoing, and the promising effects observed in the treatment arm at the 6-month read-out are

Arctic Bioscience – New cellular research showing anti-psoriatic effects

Arctic Bioscience are today presenting new research on cells at the EADV congress in Amsterdam. These cellular data show anti-psoriatic effects from phospholipid esters from herring roe oil in immune cells and skin cells. These data contribute to the understanding of how the investigational medicinal product HRO350 could impact psoriasis, and are supportive data to the ongoing clinical development program, where the ongoing phase 2b HeROPA clinical trial in mild-to-moderate psoriasis has a planned read-out later in September/early October 2024."We are very pleased to present additional

Arctic Bioscience – Mandatory notification of trade

Ronja Capital AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today transferred 3,087,999 shares in Arctic Bioscience to Ronja Capital Investment AS at an average price of NOK 13,50 per share. Both companies are controlled by Roger Halsebakk and closely related to board member Tore Tønseth in Arctic Bioscience AS.After the transaction Ronja Capital AS holds 0 shares and Ronja Capital Investment AS holds 3,087,999 shares in Arctic Bioscience AS, corresponding to an ownership of 12.17 % of the issued and outstanding share

Arctic Bioscience - Study de-risked by all needed patients passed 6 months, read-out expected in 4-6 weeks

Highlights H1 2024: · The HeROPA clinical trial fully recruited in January 2024 and proceeding as planned, de-risked by sufficient number of patients has passed the 6 months milestone · 6-months primary end-point read-out is expected ultimo September/early October · Recently published mode-of-action research showed positive effects on cells related to resolution of inflammation of phospholipid esters from HRO350 · Nutra revenues in H1 2024 totalling NOK 16,7 million (NOK 19,1 million). Revenue prospects for H2 2024 are positive · Booked sales and received purchase orders at

Arctic Bioscience – Invitation to presentation of half year 2024 results

Arctic Bioscience will publish its financial results for the first half year of 2024 on Thursday 29[th] of August, at 08:00 CET.The same day at 11:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience. Webcast details: Date: Thursday 29[th] of August 2024 Time: 11:00 CET Format: Webcast and Q&A Language: English The presentation can be accessed through the Company’s website, or with the link below: Link: https://channel.royalcast.com/landingpage/

Arctic Bioscience – Mandatory notification of trade

Nils Erik Bjørkedal, a person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has bought 10.000 shares in Arctic Bioscience at an average price of NOK 10,42 per share. Following the transaction, Nils Erik Bjørkedal holds 10.000 shares in Arctic Bioscience.Nils Erik Bjørkedal is closely associated with the Quality Manager in Arctic Bioscience, Jannicke Bjørkedal. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR)

Arctic Bioscience – Mandatory notification of trade

Sofie H. Valderhaug, a person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 4.000 shares in Arctic Bioscience at an average price of NOK 10,50 per share. Following the transaction, Sofie H. Valderhaug holds 4.000 shares in Arctic Bioscience.Sofie H. Valderhaug is closely associated with the CEO of Arctic Bioscience, Christer Valderhaug. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19

Arctic Bioscience – New positive data showing anti-inflammatory effects of phospholipid esters from herring roe in immune cells

Arctic Bioscience are today presenting a new data on anti-inflammatory cellular functions of herring roe oil at the 9th European Workshop on Lipid Mediators in Edinburgh, UK."We are very pleased to announce new positive data on the anti-inflammatory properties related to our investigational medicine, HRO350. The data show an effect on cells which may also have benefit in other inflammatory diseases, which we will explore further", says CEO Christer L. Valderhaug. “These data are important because they illuminate a mechanism of action of HRO350, which is currently being tested in a phase

Arctic Bioscience – Q1 2024 Operational update – Progress according to plan

Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as planned   · Available liquidity end of Q1 2024 of NOK 74,6 million · Above 90 % of the total nutra 2023-revenues already secured in 2024 via sales and received purchase orders · Strong growth in the Norwegian Romega market in Q1 2024The HeROPA clinical trial was fully recruited in January 2024. Since then, the clinical trial has progressed according to plan towards 6 months primary end points read-out in second half of 2024. “As the time for read-out is

Arctic Bioscience – Notice of Annual General Meeting on 26 April 2024

Arctic Bioscience AS’ Annual General Meeting will be held Friday 26 April 2024 at 11:00 (CET), as a digital meeting.Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions. Deadline for registration of attendance, advance votes, proxy or instructions is 24 April 2024 at 16:00 (CET). For attendance to the live event, please follow the instruction in the notice. For further information, see the attached Notice of the Annual General Meeting, which can also be accessed from the company’s

Arctic Bioscience – Annual report 2023

Arctic Bioscience has today released its Annual Report 2023, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 8[th] of April 2024.The report is attached to this stock notice and is available on the company’s website. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe